Optimizing expression of active botulinum toxin type A

Details for Australian Patent Application No. 2012211346 (hide)

Owner Allergan, Inc.

Inventors Fernandez-Salas, Ester E.; Steward, Iance E.; Li, Shengwen; Gilmore, Marcella A.; Miller, Ronald G.; Aoki, Kei Roger

Agent Davies Collison Cave

Pub. Number AU-A-2012211346

Parent 2005271372

Filing date 3 August 2012

Wipo publication date 30 August 2012

International Classifications

C12N 15/00 Mutation or genetic engineering

A61K 39/08 Medicinal preparations containing antigens or antibodies - Clostridium, e.g. Clostridium tetani

C07K 14/33 Peptides having more than 20 amino acids

Event Publications

16 August 2012 Complete Application Filed

30 August 2012 Application Open to Public Inspection

  Published as AU-A-2012211346

Legal

The information provided by the Site not in the nature of legal or other professional advice. The information provided by the Site is derived from third parties and may contain errors. You must make your own enquiries and seek independent advice from the relevant industry professionals before acting or relying on any information contained herein. Check the above data against the Australian Patent Office AUSPAT database.

Next and Previous Patents/Applications

2012211347-Polypeptides and antibodies derived from chronic lymphocytic leukemia cells and uses thereof

2012211345-Auxiliary device for the installation of plate-shaped products for covering floors and/or walls